Selecting b-thalassemia patients for gene therapy: a decision-making algorithm by Baronciani, D et al.
1
Guideline Article - Expert opinion
Powered by EHA
OPEN ACCESS
1UOC Immunoematologia e Trasfusionale, AORMN, Pesaro-Fano, Italy
2Università degli Studi della Campania «Luigi Vanvitelli», Napoli, Italy
3Dipartimento di Medicina, Università di Verona & AOUI Verona, Italy
4Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Malattie Rare, Milano, Italy
5Centro Microcitemie-Pediatria, AOU San Luigi Gonzaga, Orbassano (TO), Italy
6Ospedale Pediatrico Microcitemico “A.Cao,” A.O. “G.Brotzu,” Cagliari, Italy
7Divisione di Malattie Rare del Sangue e degli Organi Emopoietici, Ospedale V. Cervello, Palermo, Italy
8Centro della Microcitemia e Anemie Congenite, E.O. Ospedali Galliera, Genova, Italy
9Hematology Day Service, SOC Oncologia, Ospedale Cardinal Massaia, Asti, Italy
10Società Italiana Talassemie ed Emoglobinopatie (SITE), Roma, Italy
11Dept. of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
12CEINGE Biotecnologie Avanzate, Naples, Italy
Supplemental digital content is available for this article.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open-access article distributed 
under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the 
work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
HemaSphere (2021) 5:5(e555). http://dx.doi.org/10.1097/HS9.0000000000000555.
Received: 17 November 2020 / Accepted: 9 March 2021
Selecting β-thalassemia Patients for Gene 
Therapy: A Decision-making Algorithm
Donatella Baronciani1, Maddalena Casale2, Lucia De Franceschi3, Giovanna Graziadei4, Filomena Longo5, 
Raffaella Origa6, Paolo Rigano7, Valeria Pinto8, Monia Marchetti9, Antonia Gigante10, Achille Iolascon11,12  
(on behalf of, & Chair of, the EHA Scientific Working Group on Red Cells and Iron), Gian Luca Forni8
Correspondence: Gian Luca Forni (Gianluca.forni@galliera.it)
Abstract
This expert opinion originally developed by a panel of the Italian Society of Thalassemias and Hemoglobinopathies (SITE), reviewed 
and adopted by the European Hematology Association (EHA) through the EHA Scientific Working Group on Red Cells and Iron, has 
been developed as priority decision-making algorithm on evidence and consensus with the aim to identify which patients with transfu-
sion-dependent beta-thalassemia (TDT) could benefit from a gene therapy (GT) approach. Even if the wide utilized and high successful 
allogeneic hematopoietic stem-cell transplantation provides the possibility to cure several patients a new scenario has been opened 
by GT. Therefore, it is important to establish the patients setting for whom it is priority indicated, particularly in the early phase of the 
diffuse use outside experimental trials conducted in high selected centers. Moreover, actual price, limited availability, and resources 
disposal constitute a further indication to a rational and progressive approach to this innovative treatment. To elaborate this algorithm, 
the experience with allogeneic transplantation has been used has a predictive model. In this large worldwide experience, it has been 
clearly demonstrated that key for the optimal transplant outcome is optimal transfusion and chelation therapy in the years before the 
procedure and consequently optimal patient’s clinical condition. In the document, different clinical scenarios have been considered 
and analyzed for the possible impact on treatment outcome. According to the European Medicine Agency (EMA) for the GT product, 
this expert opinion must be considered as a dynamic, updatable, priority-based indications for physicians taking care of TDT patients.
Introduction
The Società Italiana Talassemie ed Emoglobinopatie (Italian 
Society of Thalassemias and Hemoglobinopathies [SITE]) has 
developed this expert opinion based on multidisciplinary dis-
cussions of a panel of experts to provide guidance on the iden-
tification and selection of patients with transfusion-dependent 
beta-thalassemia (β-TDT) who could benefit from gene therapy. 
The European Hematology Association (EHA), through the 
EHA Scientific Working Group (SWG) on Red Cells and Iron, 
has furthered the initiative through an international panel of 
reviewers and adopted these suggestions. This is the second ver-
sion, March 2020; translated and edited, August 2020.
Currently, allogeneic transplantation of hematopoietic stem cells 
is the only curative and most widely used therapy treatment for 
β-TDT. However, recent trials of gene therapy have reported very 
promising results in terms of overall survival1–3 and thalassemia-free 
survival and are opening a new landscape of treatment. This algo-
rithm for the selection of patients suitable for gene therapy and 
the supporting notes were formulated by consensus review after an 
evaluation of currently available scientific evidence using validated 
criteria. The evidence was interpreted with caution because clinical 
trial experience of gene therapy is currently limited, a conventional 
treatment is available for patients with β-TDT and the availability 
of gene therapy will, at least initially, be quite limited.
Clinical experience of allogeneic transplantation in β-TDT, 
which began in 1981, immediately showed the importance of 
patient risk stratification to achieve the best results4–6 (see the 
Pesaro experience and their classification of patients accord-
ing to risk). Published data in the literature and the recent 
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analysis of clinical evidence by the European Registry of 
Hemoglobinopathies of a large number of patients (2011 and 
2018 analyses) confirm that young patient age (<14 yrs) and the 
availability of a human leukocyte antigen (HLA)-identical fam-
ily donor are factors that offer the best outcome from allogeneic 
transplantation.6–10
Current knowledge of, and experience with, nonconventional 
treatments, such as allogeneic transplantation and gene therapy, 
are discussed to identify the best available treatment and indica-
tion for these patients according to their characteristics.
At this point in time, when we can see the emergence of “the 
age of gene therapy” and recent preliminary results on gene 
editing are promising,11 it is essential to establish the optimal 
patient setting in which gene therapy can be applied, or better, 
to define the setting that represents the most suitable indication 
for gene therapy, identify the patients who should have clinical 
priority for access to the procedure, and set out requirements 
and recommendations for the identification of qualified treat-
ment centers for gene therapy. When considering changes to the 
treatment of patients with β-TDT, including gene therapy, it is 
essential that a detailed consultation is held with the patient and 
their caregiver/family to discuss all possible risks and potential 
benefits from the treatment. Discussion of this aspect of care is 
outside the scope of this expert opinion but remains an import-
ant element of patient care.
Methods
The current expert opinion describes the different clinical 
problems with practical conclusions on each aspect of the subject, 
and is summarized by a decision-making algorithm (Figure 1). A 
Supplemental Digital Appendix, http://links.lww.com/HS/A156, 
is also included in the supplementary information, providing 
details on the requirements and recommendations for the identi-
fication of qualified gene therapy treatment centers.
The decision-making algorithm was developed by the SITE 
group, who defined the project and selected a multidisciplinary 
group of experts in hemoglobinopathies and/or transplanta-
tion to discuss the selection of β-TDT patients for gene therapy 
and draw up notes on the related clinical problems. The EHA, 
through the EHA SWG on Red Cells and Iron, has furthered 
the initiative through an international panel of reviewers and 
adopted these suggestions. The expert opinion has been pre-
pared to be used by specialists in the centers of the Networks of 
Hemoglobinopathies.
The published literature (Medline, PubMed, Embase, and 
Cochrane Library) was searched for high-quality evidence to 
define the best candidates for allogeneic transplantation who 
should not undergo gene therapy. The keywords used were 
beta-thalassemia; bone marrow transplantation; gene therapy; 
hematopoietic stem cell (HSC) transplantation; hemoglobinop-
athies; hepatitis; iron overload; liver complications; endocrine 
complications.
The literature evaluation/scientific evidence was reported and 
discussed by the SITE expert panel. The final version of the docu-
ment was then assessed by a pool of external reviewers with mod-
ifications made as appropriate and the final version of the expert 
opinion will be uploaded onto the SITE website (www.site-italia.
org). It is intended that the results of the process will be collected 
in the clinical electronic database used by the centers (eg, Webthal, 
International Health Repository) to carry out stratification.
The SITE group would like to emphasize the approach used 
for evaluating β-TDT patients’ access to gene therapy. Until a 
few decades ago, β-TDT was considered an unfavorable pathol-
ogy. Today, however, β-TDT has an open prognosis thanks to 
advances in conventional treatment that have transformed 
it into a chronic disease. It was therefore decided, in this first 
phase of access to gene therapy, to give priority to patients 
in the best clinical condition who, as shown in the allogeneic 
transplantation setting, are those who are likely to obtain the 
most clinical benefit with the least risk. As mentioned previously 
this cautious approach is due to the limited clinical experience 
obtained during clinical trials and due to the probable limited 
availability of gene therapy, at least initially. The patient priority 
criteria for access to gene therapy defined in this algorithm and 
supporting notes could vary as new scientific evidence emerges, 
and therefore, the expert opinion will be reviewed regularly 
and updated when new clinical data are published and/or any 
changes are made to the European Medicines Agency (EMA) 
license for gene therapy.
Gene therapy: suitability requirements for 
patients with β-TDT
Suitable patients for gene therapy are included as follows:
• Patients with β-thalassemia who are transfusion dependent.
• Given the seriousness of their disease, many patients affected 
by β-thalassemia depend on a chronic regimen of blood trans-
fusions both for their survival and to prevent complications 
associated with the disease. Transfusion dependence is defined 
as no transfusion-free period of >6 weeks in the last 2 years or 
the transfusion of a minimum 100 mL/kg of concentrated red 
blood cells/year in the last 2 years.2
• Patients with β-TDT who are followed at “Centers experi-
enced in the treatment of beta thalassaemia” according to 
the EMA prescription or at “Hemoglobinopathies Reference 
Centers” for the countries, like Italy, where a specialized net-
work, recognized by institutions, exists.12,13 In consideration 
that not all countries have such specialist centers, we recom-
mend that a summary of the below described information 
must be available.
• At hemoglobinopathies specialized centers, it is possible to 
track clinical data, particularly data related to transfusion. 
At these centers, the patient also has a preliminary interview 
during which the available therapeutic options and the pro-
posed procedures are discussed. The transplant center will 
carry out the final interview and final assessment and collect 
the patient’s informed consent form.
• It is essential that patients are followed at a hemoglobinop-
athies specialized center for at least 2 years and that correct 
registration of medical data is guaranteed, with attention to 
data concerning comorbidities, laboratory and instrumental 
test results, and blood transfusions.
• Traceability of blood transfusion data is particularly important 
to calculate annual transfusion and iron intake requirements, 
to register any alloantibodies and transfusion reactions, and to 
evaluate the need for any further therapy after gene therapy.
Patient age
Background and discussion
It is now clear that age is a risk factor for clinical outcomes 
in patients with hemoglobinopathies both during conven-
tional therapy and in a transplant setting. In the 1980s, the 
Pesaro Group stratified thalassemic patients aged <16 years 
into 3 different risk groups that had a significant impact 
on the clinical outcome after transplantation. The statisti-
cally significant factors were hepatomegaly (<2 versus >2 cm 
from the costal margin), hepatic fibrosis (absent versus pres-
ent), and chelation (regular versus irregular).4,5,14 This last 
parameter was linked to the use of deferoxamine, the only 
chelating drug then available and importantly it reflected the 
concept of duration and exposure to iron overload and tox-
icity. However, the Pesaro Classification was not predictive 
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of clinical outcomes in adult patients with β-TDT, probably 
because they had already been exposed to iron chelation for 
too long. The correlation between the Pesaro Classification 
and our current understanding of the physiopathology of 
iron has now been recognized and has received fresh inter-
pretation15,16; in itself, it underlines the pertinence today of 
the observation reported almost 30 years ago. However, the 
limited experience of gene therapy in clinical trials to date 
requires the adoption of a cautious approach when using the 
Pesaro classification of risk for patients undergoing gene ther-
apy until novel evidence becomes available.
Age is also considered and established by the current regula-
tions in force. In fact, gene therapy using LentiGlobin (Blubird 
Bio) has received the EMA approval for patients aged >12 years 
with β-TDT with non-β0/β0 genotype.17
It is important to note that the safety and efficacy of gene 
therapy in children aged <12 years has not been established.
Concerning children under the age of 12 they cannot be con-
sidered in this expert opinion because current EMA regulation 
excludes them from gene therapy because safety and efficacy of 
gene therapy in children aged <12 years has not been established. 
Children indication will require dedicated trials including a suf-
ficient number of patients. It should be noted that the vector 
“GLOBE” that showed promising results in young children18 is 
actually not registered by any regulatory authority worldwide.
The upper age limit for gene therapy has not been fixed as it 
depends on the clinical condition (comorbidities/organ damage) 
of each individual. It is therefore up to the physician to examine 
the characteristics of their patient and evaluate the clinical pri-
orities to be addressed.
Up to now, limited data are available regarding the impact 
of the aging process on medullary microenvironment in healthy 
subjects. Studies carried out in elderly subjects (aged >65 yrs) 
have shown how mobilization of CD34+ cells with granulo-
cyte-colony stimulating factor can be reduced, but always on 
the basis of transplant requirements.19–21 In nonanemic older 
patients aged between 66 and 73 years, 2 independent stud-
ies have described a reduction in circulating CD34+ cells com-
pared with younger subjects associated with age-dependent 
increased serum stem cell factor, indicating an age-dependent 
change in hematopoietic cytokine(s).22–24 Inadequate erythro-
poietin (EPO) production has been suggested to contribute to 
anemia in the elderly, but again limited and not conclusive stud-
ies are available. Furthermore, the presence of a comorbidity 
such as diabetes, arterial hypertension, or kidney failure might 
further alter the cellular response to EPO.21,25 Finally, bone mar-
row microenvironment is dynamically changing during aging 
and it might represent an additional factor to be taken into 
consideration in identification of candidate patients for gene 
therapy.26,27
Recommendations
• Gene therapy products are today registered over the age of 11 
years.
• Patients >50 years old must be considered with caution.
• We do not recommend gene therapy in patients aged over 55.
Allogeneic transplantation
Background and discussion
The 2 key factors that determine eligibility for allogeneic 
transplantation and affect clinical outcomes after transplan-
tation are age and the availability of an HLA-identical family 
donor.
Currently, the European Hemoglobinopathies Registry states 
that allogeneic transplantation should take place in patients 
who are <14 years old. The correlation between age and clini-
cal outcome is directly related to the iron-related organ damage 
that results from long-term repeated blood transfusions, despite 
Figure 1. Algorithm for the selection of transfusion-dependent β-thalassemia patients for gene therapy.
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the incredible improvements seen in treatment, iron chelation, 
and other supportive measures.
HLA compatibility is also extremely important in the 
transplant setting, both because it reduces the immunological 
complications related to antigenic disparity that results in graft-
versus-host disease (GvHD) and because it allows less ablative 
and immunosuppressive conditioning regimens to be used, 
therefore reducing the transplant procedure-related toxicity and 
likelihood of infection complications.
Data from large cohort studies have confirmed that an HLA-
identical family donor is the donor profile that guarantees the 
best outcome in terms of overall survival and thalassemia-free 
survival. Data from the European Hemoglobinopathies Registry 
show that patients aged <14 years with an HLA-identical fam-
ily donor have an overall survival rate of 91.9% and thalas-
semia-free survival of 86%.9,28 Recently, experiences evaluating 
transplantation with matched unrelated donors and haploiden-
tical donors in patients with β-TDT have been published with 
relevant results.8,29,30
Recommendations
• Patient age <14 years and HLA-identical family donor are 
the factors associated with the best transplant outcomes in 
patients with β-TDT.
Genotype
A patient’s β-globin genotype must be registered on presenta-
tion of a report from a National Health accredited laboratory.
The HbVar database (http://globin.cse.psu.edu) can be used 
to define hematologic expression (β0 o β+ forms).
At present, regulatory authorities do not request studies of 
alfa, delta, and gamma globin genes. However, the complete 
molecular globin profile of a patient could be useful in assessing 
their expected response to therapy.
Recommendations
• Identification of a patient’s complete molecular globin profile 
is strongly advised before starting gene therapy.
Iron overload
Background and discussion
The experience of the Pesaro group showed that constant 
monitoring of the level of iron accumulation is the determining 
factor for transplant outcome.10 The Pesaro classification14 (val-
idated for patients < 18 yrs only), which stratifies patients on the 
basis of 3 independent factors (hepatomegaly, hepatic fibrosis, 
and length of exposure time to chelating therapy), remains per-
tinent today because it highlights the importance of monitoring 
iron accumulation throughout a patient’s lifetime.16,31 Moreover, 
an elevated LIC (as any elevated iron burden biomarker) is a 
sign of years of exposure to toxic forms of iron16 and parallel 
chelation compliance and tissue damage.
According to the formula recently proposed by Coates,15 
iron-associated tissue toxicity is due to more than a single 
factor: the quantity of reactive species (non-transferrin bound 
iron, labile plasma iron, etc.); genetic antioxidant factors 
(superoxide dismutase, catalase, and glutathione peroxidase); 
environmental factors (food antioxidants, other metals such as 
copper and selenium); and length of time exposed to the toxic 
effects of iron.
Recent in vitro studies32,33 have shown that accumulation of 
iron can also influence the medullary bone marrow microenvi-
ronment and have a negative impact on both the quality and the 
quantity of the hematopoietic stem progenitor cells.
In relation to iron accumulation, when considering gene ther-
apy, attention should be drawn to the paragraph in the Zynteglo 
EMA product approval documentation entitled “Risks associ-
ated with TDT and iron overload,” section 4.4 Special warn-
ings and precautions for use in Supplemental Digital Appendix 
I, http://links.lww.com/HS/A156—Summary Of Product 
Characteristics used for gene therapy and approved by the 
EMA34: “Patients with TDT experience iron overload due to 
chronic red blood cell (RBC) transfusions that can lead to end 
organ damage. HSC transplantation with myeloablative con-
ditioning is not appropriate for patients with TDT who have 
evidence of severely elevated iron in the heart i.e., patients with 
cardiac T2* <10 ms by magnetic resonance imaging (MRI). 
MRI of the liver should be performed on all patients prior to 
myeloablative conditioning. It is recommended that patients 
with MRI results demonstrating liver iron concentration (LIC) 
≥15 mg/g undergo liver biopsy for further evaluation. If the liver 
biopsy demonstrates bridging fibrosis, cirrhosis, or active hep-
atitis, HSC transplantation with myeloablative conditioning is 
not appropriate.” Adopting a cautious approach, the SITE feels 
that more stringent iron accumulation criteria should be used 
than those indicated by the EMA (≥15 mgFe/g Liver, see above).
Recommendations
• Patients with significant iron accumulation (LIC > 7 mgFe/g 
Liver) should have a “suspended indication” for gene ther-
apy until values return to acceptable limits (LIC < 7 mgFe/g 
Liver).
• Caution should be exercised and iron levels should be strictly 
monitored after adequate chelation therapy has been set up.
Cardiomyopathy
Background and discussion
In patients with β-TDT, cardiac complications and prema-
ture death due to cardiomyopathy represent a serious problem. 
Iron-related cardiac damage manifests as cardiac insufficiency, 
arrhythmias, sudden death, or progressive congestive heart failure. 
Overall, iron-related cardiac complications are the leading cause 
of death and the biggest cause of morbidity in these patients.35,36
In patients with β-TDT, the outcome of allogeneic trans-
plantation is directly correlated with good performance status, 
adequate iron chelation without iron-related organ damage, 
and the absence of comorbidities.37 These same parameters 
also influence clinical outcomes of gene therapy in this patient 
population.37
The prevalence and predictive factors for cardiac complica-
tions in patients undergoing allogeneic transplantation are not 
known. In clinical trials of gene therapy in patients with β-TDT, 
a heart T2* MRI <10 ms and clinically significant pulmonary 
hypertension are conditions that should exclude access to gene 
therapy.2 In the light of observations on restrictive myocardi-
opathy in adult patients with preserved ejection fraction and 
without myocardial iron overload, the SITE panel consider that 
these factors should be included in the exclusion criteria.
Recommendations
The following heart conditions should be considered exclu-
sion criteria:
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• myocardial iron overload T2* MRI <10 ms in the previous 6 
months38,39;
• pulmonary hypertension (determined by cardiac cathete- 
rization)40;
• serious congestive heart failure (New York Heart Association 
class III or above);
• significant arrhythmia requiring therapy, as defined by the 
European Heart Rhythm Association (EHRA) guidelines41;
• myocardial ischemia in the previous 12 months, as defined by 
the European Society of Cardiology (ESC) guidelines41;
• restrictive myocardiopathy, as defined by ESC guidelines.41
Liver disease
Background and discussion
Follow-up data on outcomes following gene therapy are 
lacking. It is therefore useful to refer to clinical experience from 
hematopoietic stem cell transplants in this setting. In 1990, 
Lucarelli et al5 identified fibrosis and hepatomegaly as factors 
predictive of a negative transplant outcome and, despite the sub-
sequent controversy concerning the definition of hepatomegaly, 
these original criteria are still considered valid (ie, hepatomegaly 
is an expression of hepatic iron accumulation and of the dura-
tion of toxic iron exposure).16
Hepatic fibrosis
Hepatic fibrosis is a marker of exposure to iron and to viruses. 
Patients with liver disease, and particularly those with severe 
hepatic fibrosis or cirrhosis, are at higher risk of veno-occlusive 
disease (VOD) after myeloablative conditioning regimens and 
are also at increased risk of fatal liver failure even with reduced 
intensity conditioning.42 Assessment of the level of liver fibrosis 
should ideally be determined for all potential gene therapy can-
didates before treatment is started.
Hepatitis C virus infection
Data correlating hepatitis C virus (HCV) infection with gene 
therapy is lacking because patients who test positive for HCV-
RNA are not usually enrolled into clinical trials. It is useful, 
therefore, to refer to the experience from hematopoietic stem 
cell transplants in patients with β-TDT to guide the selection 
of gene therapy candidates. HCV infection (ie, HCV-RNA pos-
itivity) appears to be clinically relevant in this setting, as hep-
atitis can worsen after immune reconstitution.43 The risk of 
death after virus reactivation is 8% and involves the allogeneic 
transplant setting only. HCV-positivity is therefore generally 
considered to be a significant risk factor in patients with β-
TDT undergoing transplantation; patients with HCV have an 
increased risk of death after allogeneic stem cell transplantation 
even if they have normal or almost normal liver function.44 The 
association between HCV status and the risk of posttransplant 
VOD remains a subject of debate and is not supported by all 
experts. However, some experts consider HCV to be an indepen-
dent risk factor for posttransplant VOD.45,46 An increase in the 
risk for fatal VOD in HCV-positive patients who had received 
cyclophosphamide and >12 Gy total body irradiation has been 
observed, but this seems to be correlated to liver inflammation 
and fibrosis and to the components of the conditioning regi-
men rather than the HCV itself.46 Considering the availability 
of effective and safe antiviral therapies that have demonstrated 
excellent results also in thalassemia patients, it does not seem 
justified to consider HCV-RNA-positive subjects as candidates 
for gene therapy.47–50
Hepatitis B virus infection
As stated previously, due to the lack of data for gene therapy in 
this setting, it is useful to refer to the experience of hematopoietic 
stem cell transplant to address this issue. In patients with β-TDT 
who have undergone hematopoietic stem cell transplant, hepati-
tis B virus (HBV) virus reactivation can be followed by normal-
ization with seroconversion until HbsAg negativity is achieved 
in 25% of cases, even without antiviral therapy, while fulminant 
hepatitis is observed in a small percentage of patients (3%). 
In most cases, any new acute phase of hepatitis is only light 
and asymptomatic with a moderate and long-lasting increase 
in transaminase levels.51 The risk of reactivation of hepatitis 
B in HbsAg negative and anti-HBc positive subjects is around 
6.5%. There are no observed differences between patients who 
are HBV-DNA positive and those who are HBV-DNA negative; 
among those with hematologic diseases, the risk of reactivation 
is higher in those treated with rituximab.52
Clinical presentation of HBV reactivation ranges from 
asymptomatic cases to acute liver failure and death. Mortality 
rates are higher in those patients who do not receive antiviral 
agents compared with those who do (~30% versus 12%, respec-
tively); moreover, among those patients treated with antiviral 
agents, mortality rates are lower in those treated with entecavir 
compared to those treated with lamivudine.53 The use of anti-
HBV prophylaxis is therefore recommended in patients who are 
HbsAg-negative, anti-HBc-positive with hematologic diseases, 
irrespective of the patient’s basal anti-HBs and HBV-DNA sta-
tus. In addition, treatment with the second-generation nucleo-
side analogs (eg, entecavir/tenofovir) is strongly recommended 
for patients with active chronic HBV infection who are candi-
dates for immunosuppressive therapy.54
Recommendations
• The ideal candidates for gene therapy are patients with β-
TDT who have no or only slight hepatic fibrosis, which in 
this context the SITE defines as level F1 based on Fibroscan 
or Ishak stage 0-1-(2) based on liver biopsy.
• There are no reasons to consider anti-HCV-positive patients 
to be contraindicated for gene therapy if they have eliminated 
the virus either spontaneously or after anti-viral therapy, 
provided that they have no other hepatic or extra-hepatic 
contraindications.
• Gene therapy is contraindicated in patients with chronic 
HBV infection, as defined by the European Association for 
the Study of Liver (EASL) guidelines.
• Gene therapy can be considered for patients who have occult 
HBV infection, as defined by the EASL guidelines, provided 




Appropriate long-term medical treatment is the essential 
factor for good clinical outcomes after hematopoietic stem cell 
transplants,37 and this is probably also the case for patients 
undergoing gene therapy. Endocrinopathies (eg, diabetes, 
hypogonadism, short stature, and hypothyroidism) have been 
shown to be associated with higher ferritin levels,55 as in cases 
when patients started iron chelation therapy late,56 and cardiac 
overload,57 indicating that the presence of one or more endo-
crinological complications usually reflects an inadequate iron 
chelation therapy and therefore a high iron burden for the 
patient concerned.56,58
The term “diabetic stem cell mobilopathy” is used to indi-
cate scarce mobilization of the bone marrow hematopoietic 
stem cells to the peripheral blood in patients with diabetes. 
This occurs because diabetes radically changes the bone 
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marrow microenvironment resulting in a net reduction in the 
release of hematopoietic stem cells.59 In clinical trials of gene 
therapy, the presence of an endocrinopathy has never been 
an exclusion criterion. However, exclusion criteria have been 
reported to include the statement: “Any other evidence of 
severe iron overload that, in the Investigator’s opinion, war-
rants exclusion.”2
Endocrinological complications have not been shown to 
be relevant to the posttransplant outcome. These should, 
however, always be assessed before hematopoietic stem cell 
transplant to plan adequate monitoring of these conditions 
posttransplant.60
Recommendations
• A cautious approach should be adopted at this stage given the 
limited clinical experience with gene therapy.
• Insulin-dependent patients should not be considered high-pri-
ority patients for gene therapy.
Nephropathy
Background and discussion
In patients with β-TDT, kidney damage can be related either 
to iron overload or to chronic hypoxia caused by anemia.60 In 
this setting, experience from allogeneic hematopoietic stem cell 
transplantation cannot be applied to the use of nephrotoxic 
immunosuppressors.
Different thresholds used to define chronic disease have been 
reported in the literature. Examples include: “kidney disease 
with a calculated creatinine clearance <30% normal value”60; 
“kidney disease with a baseline estimated glomerular filtration 
rate <70 mL/min/1.73 m2”2; or “adequate renal function as evi-
denced by serum creatinine <1.5 upper limit of normal.”18
Published clinical trials on the use of gene therapy in patients 
with β-TDT patients report that changes in kidney function are 
an exclusion criterion for clinical trial enrollment.
Recommendations
• Kidney function must be assessed before starting gene therapy.
• Patients with abnormal renal function should be considered 
for gene therapy with extreme caution and are not given pri-
ority at this stage.
Thrombophilic status
Background and discussion
Patients with β-TDT present with hypercoagulability (which 
is particularly evident in splenectomized patients) due to a high 
platelet count and peripheral erythroblastosis.60–64
Due to peripheral stem cell mobilization and the use of gran-
ulocyte-colony stimulating factor during gene therapy, patients 
with a history of thrombotic events must be identified and their 
thrombophilic status assessed before being considered eligible 
for gene therapy.18,65 Clinical studies of the use of gene therapy 
in patients with β-TDT have confirmed that a history of throm-
botic events should be an exclusion criterion for enrollment; 
hypersplenism should also be a contraindication as it can have a 
negative impact on grafting.
Assessment of/screening for prothrombotic status before 
treatment is essential to confirm patient suitability and to pro-
mote good outcomes from gene therapy.
Recommendations
• Patients with a “low-risk thrombophilic screen” (defined here 
as low levels of protein S, protein C, and/or antithrombin III) 
are not excluded from gene therapy as these may be related to 
thalassemic/sickle cell liver damage.18
• Patients with a remote history of a thromboembolic event and 
no documented pulmonary hypertension can be evaluated for 
gene therapy after the suspension of anticoagulant therapy.
• Patients with a negative history of significant previous throm-
botic events are considered eligible for enrollment.18
• Hypersplenism is a contraindication for gene therapy.2
• Patients with white blood cell count <3 × 109/L, and/or plate-
let count <100 × 109/L are exclusion criteria (ie, pancytopenia 
postinfection).2
• Lupus anticoagulant represents a contraindication to gene 
therapy; an uncorrected bleeding disorder (eg, low levels of 
Factor VII or VIII) is also an exclusion to treatment.
Summary of recommendations
Patient selection must be carried out through a con-
sensus decision between the Center of the Network of 
Hemoglobinopathies and the treatment center qualified to carry 
out HSC transplantation.
Gene therapy should be restricted to centers experienced with 
myeloablative conditioning and with the treatment of transfu-
sion-dependent β-thalassemia. Patients selected for gene ther-
apy must fulfill the inclusion criteria established for LentiGlobin 
European Medicines Authority (EMA) license and be accredited 
by the Foundation for the Accreditation of Cellular Therapy and 
Joint Accreditation Committee (FACT-JACIE) for allotransplant.
It is the opinion of the expert panel that patients with β-
TDT who could represent possible candidates for gene therapy 
with the only product currently available that is approved by 
the EMA (EMA/CHMP/166977/209; https://www.ema.europa.
eu/en/documents/smop-initial/chmp-summary-positive-opin-
ion-zynteglo_en.pdf) (Zynteglo; https://www.zynteglo.eu/) must 
satisfy the criteria listed in the following summary Table 1.
Patients must be considered unsuitable for gene therapy if they:
1. meet exclusion criteria indicated by the regulatory 
authorities (see EMA/CHMP/166977/2019; https://
www.ema.europa . eu / en /document s / smop- in i t i a l /
chmp-summary-positive-opinion-zynteglo_en.pdf);
2. have uncontrollable iron overload and/or chronic organ dam-
age (eg, pulmonary hypertension).
Controllable iron overload requires reassessment. Caution 
must be exercised when assessing patients with complications 
and comorbidities.
Access to gene therapy must be reassessed according to scien-
tific and regulatory updates.
In recognition of the continuous evolution of medical scien-
tific knowledge, of new data being presented in the literature 
and, in specific cases, of changes to recommendations from the 
regulatory authorities, the SITE and EHA expert panels will 
update this algorithm and the supporting notes when new evi-
dence is published that could modify the strength of the current 
recommendations. As these technologies will likely improve over 
time, the inclusion or change in some parameter may happen; 
for example, more effective vectors (β0 patients), less myeloab-
lation, or nontoxic regimens, novel medications that improve 
some of the conditions related to iron overload.
Should no such evidence emerge, the SITE and EHA expert 
panel will review and update the algorithm and supporting 
notes every 2 years.
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